This phase I/II clinical study will evaluate the ability of a new type of vaccine, Nous-209, in combination with another drug, pembrolizumab (also called Keytruda), to provide a beneficial effect as a treatment for certain types of colorectal cancer (CRC). About Nous-209 and Pembrolizumab Nous-209 is a genetic vaccine that ...
May 2024 According to a recent study published in Microbiology Spectrum, specific microbiome “signatures” were associated with KRAS mutations in patients with colorectal cancer (CRC). These signatures include unique microbiome characteristics such as the presence of specific bacteria, which may serve as a biomarker or indicator for the presence of ...
May 2024 A recent study published in the Journal of Immunotherapy and Precision Oncology suggests that the makeup of the gut microbiome may reveal distinct characteristics or signatures associated with race, ethnicity, and age of onset in patients diagnosed with colorectal cancer (CRC). The gut microbiome refers to the trillions ...
While treatment may be lifesaving, many folks experience a wide variety of treatment side-effects that lead to a reduction in quality of life and an increase in stress. Some of these side-effects may include extreme fatigue, nausea, brain fog, insomnia or troubles sleeping, reduction in the immune system, and troubles ...
This study aims to investigate dostarlimab therapy in patients with locally advanced mismatch-repair deficient (dMMR) / microsatellite instability high (MSI-H) rectal cancer who have not received any previous treatment. Patients who achieve a complete clinical response (no detectable tumour remains)...
Benefits of family support Family is one of the most important sources and support systems that patients have (Faraji et al., 2023; Sebastian et al., 2022). When patients have a strong network to rely on, they can dedicate more of their time to their treatment and other issues they are ...
April 2024 A recent study published in the Journal of Clinical Oncology found that Helicobacter pylori infection was associated with a greater risk of developing colorectal cancer and an increased risk of dying from it (mortality). Helicobacter pylori is a type of bacteria that infects the stomach. Infection can damage ...
April 2024 Refractory cancer: cancer that does not respond to treatment Fruquintinib (Fruzaqla) is a targeted therapy used in the treatment of patients with heavily pretreated metastatic colorectal cancer. It is a treatment that is used when other standard of care treatments such as fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF ...
1 Westmount Square, Suite 1630
Westmount, QC H3Z 2P9
Canada
info@colorectalcancercanada.com
© Colorectal Cancer Canada All rights reserved
Charitable registration number 86657 2423 RR0001
